In addition, the identification of a gene signature associated with BC cell sensitivity to CD32-CR T cells and predicting the favorable clinical course of BC in a retrospective study of 1,400 patients with advanced disease opens new unsuspected investigation pathways in the field of innate cell and tumor biology. The gene discussed is FCGR2A; the disease is neoplasm.